Human papillomavirus: burden of illness and treatment cost considerations.
The monetary and personal costs to society of human papillomavirus (HPV) infection are enormous. In order to make a comparison of different treatment methods we reviewed the entire literature on HPV treatment from January 1966 to December 2003 using MEDLINE, with particular reference to published meta-analyses, randomized controlled and comparative studies. Patient-applied therapies offer patients the possibility of convenient and, on the whole, pain-free treatment. Podofilox (podophyllotoxin) and salicylic acid for genital and extragenital warts, respectively, have the additional advantage of being the most cost-effective treatments and, on this basis, they are to be commended as appropriate first-line agents. The second-line treatment of choice for common warts is cryotherapy. For recalcitrant common warts possible options include inosine pranobex with cryotherapy or electrosurgery, imiquimod with paring and occlusion, intralesional bleomycin, or diphencyprone. Alternative first-line and second-line treatments for genital warts would be either some form of surgical removal or imiquimod. The first option may be the cheapest but this has to be balanced against a degree of post-operative morbidity. Limited data from comparative studies do not show any clear difference in efficacy between cryotherapy, trichloroacetic acid, scissor excision, electrosurgery, and laser surgery in the treatment of genital warts, and the cost effectiveness of these therapies is probably similar to that of imiquimod. Cryotherapy and trichloroacetic acid are relatively expensive and inconvenient for patients and should be reserved as third-line treatments with certain exceptions, such as cryotherapy for meatal warts. The duration of treatment is significantly related to the number of warts present, the area covered by the warts, and the length of time the warts have been present. For recalcitrant anogenital warts third-line treatment options that show promise include surgery in combination with imiquimod or cidofovir cream. For squamous intraepithelial lesions that cannot easily be excised or physically ablated current treatment options include imiquimod and fluorouracil cream. The latter is an inexpensive option but causes the greatest morbidity. It is hoped that cidofovir may be added to this list if it becomes commercially available, and that protective and therapeutic HPV vaccines will transform the management of HPV in the future.
Fox
Paul A
PA
Chelsea and Westminster Hospital, London, UK. paul.fox@eht.nhs.uk
Tung
Mun-Yee
MY
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000628:therapy; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D002278:Carcinoma in Situ / Q000628:therapy / Q000821:virology; D017679:Cryotherapy / Q000191:economics; D004598:Electrosurgery / Q000191:economics; D005260:Female; D006801:Humans; D007641:Keratolytic Agents / Q000627:therapeutic use; D053685:Laser Therapy / Q000191:economics; D009369:Neoplasms / Q000628:therapy / Q000821:virology; D027383:Papillomaviridae; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000628:therapy; D014765:Viral Vaccines; D014860:Warts / Q000191:economics* / Q000628:therapy*
D000970:Antineoplastic Agents; D007641:Keratolytic Agents; D014765:Viral Vaccines